Partners
Partners

Partner 35 - Terumo BCT


 

 

 

 

 

James Ladtkow

 

Engineering Director

New Product Ideation

 

 

undefinedE-Mail

 

 

Terumo BCT

 

10811 West Collins Avenue

Lakewood Colorado 80215

USA

 

undefinedWebsite

Company presentation

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

 

Terumo BCT’s Spectra Optia® Apheresis System, an FDA-cleared and CE marked device for use in therapeutic apheresis and cell collection procedures, will be incorporated into CANCER-ID research efforts that will evaluate diagnostic leukapheresis (DLA) as a means to capture and harvest larger numbers of CTCs.* This research may uncover a diagnostic application for the Spectra Optia system, which is currently used in hospitals and blood centers around the world.

 

Terumo BCT is pleased to partner with CANCER-ID, furthering the consortium’s mission of developing standards and conducting clinical validation to enable broad adoption of reliable molecular analyses from liquid biopsies.

 

 

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

developed by TATAA Biocenter and the Institute of Biotechnology, BIOCEV. Read more

Social Media

LinkedIn Cancer-ID